392 related articles for article (PubMed ID: 8596569)
1. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.
Linet OI; Ogrinc FG
N Engl J Med; 1996 Apr; 334(14):873-7. PubMed ID: 8596569
[TBL] [Abstract][Full Text] [Related]
2. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group.
Br J Urol; 1998 Oct; 82(4):538-43. PubMed ID: 9806184
[TBL] [Abstract][Full Text] [Related]
3. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group.
Padma-Nathan H; Hellstrom WJ; Kaiser FE; Labasky RF; Lue TF; Nolten WE; Norwood PC; Peterson CA; Shabsigh R; Tam PY; Place VA; Gesundheit N
N Engl J Med; 1997 Jan; 336(1):1-7. PubMed ID: 8970933
[TBL] [Abstract][Full Text] [Related]
4. Relation between intracavernosal dose of prostaglandin Pge 1 and mean duration of erection in men with different underlying causes of erectile dysfunction.
Bratus D; Hlebic G; Hajdinjak T
Croat Med J; 2007 Feb; 48(1):76-80. PubMed ID: 17309142
[TBL] [Abstract][Full Text] [Related]
5. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.
Goldstein I; Lue TF; Padma-Nathan H; Rosen RC; Steers WD; Wicker PA
N Engl J Med; 1998 May; 338(20):1397-404. PubMed ID: 9580646
[TBL] [Abstract][Full Text] [Related]
6. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
Purvis K; Brekke I; Christiansen E
Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
[TBL] [Abstract][Full Text] [Related]
7. Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations.
Peterson CA; Bennett AH; Hellstrom WJ; Kaiser FE; Morley JE; Nemo KJ; Padma-Nathan H; Place VA; Prendergast JJ; Tam PY; Tanagho EA; Todd LK; Varady JC; Gesundheit N
J Urol; 1998 May; 159(5):1523-7; discussion 1527-8. PubMed ID: 9554347
[TBL] [Abstract][Full Text] [Related]
8. The efficacy, safety and tolerability of intracavernous PNU-83757 for the treatment of erectile dysfunction.
Vick RN; Benevides M; Patel M; Parivar K; Linnet O; Carson CC
J Urol; 2002 Jun; 167(6):2618-23. PubMed ID: 11992097
[TBL] [Abstract][Full Text] [Related]
9. [Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)].
Potempal AJ; Potempa DM; Görlich HD; Stolpmann RM
Arzneimittelforschung; 2007; 57(6):299-308. PubMed ID: 17688074
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction.
Perimenis P; Konstantinopoulos A; Perimeni PP; Gyftopoulos K; Kartsanis G; Liatsikos E; Athanasopoulos A
Asian J Androl; 2006 Mar; 8(2):219-24. PubMed ID: 16491275
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a needle-free high-pressure injection system with needle-tipped injection of intracavernosal alprostadil for erectile dysfunction.
Harding LM; Adeniyi A; Everson R; Barker S; Ralph DJ; Baranowski AP
Int J Impot Res; 2002 Dec; 14(6):498-501. PubMed ID: 12494285
[TBL] [Abstract][Full Text] [Related]
12. Sexual rehabilitation and penile pain associated with intracavernous alprostadil after radical prostatectomy.
Yiou R; Cunin P; de la Taille A; Salomon L; Binhas M; Lingombet O; Paul M; Abbou C
J Sex Med; 2011 Feb; 8(2):575-82. PubMed ID: 20807323
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of transurethral application of alprostadil for erectile dysfunction in Indonesians.
Pangkahila WI
Asian J Androl; 2000 Sep; 2(3):233-6. PubMed ID: 11225984
[TBL] [Abstract][Full Text] [Related]
14. Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy.
Sexton WJ; Benedict JF; Jarow JP
J Urol; 1998 Mar; 159(3):811-5. PubMed ID: 9474156
[TBL] [Abstract][Full Text] [Related]
15. [Dose adaptation during training of intracavernous self-injections of prostaglandin E1].
Staerman F; Veilhan LA; Guiraud P; Coeurdacier P; Cipolla B; Lobel B
Prog Urol; 1996; 6(4):564-8. PubMed ID: 8924934
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED.
Padma-Nathan H; Steidle C; Salem S; Tayse N; Yeager J; Harning R
Int J Impot Res; 2003 Feb; 15(1):10-7. PubMed ID: 12605235
[TBL] [Abstract][Full Text] [Related]
17. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men.
Heaton JP; Lording D; Liu SN; Litonjua AD; Guangwei L; Kim SC; Kim JJ; Zhi-Zhou S; Israr D; Niazi D; Rajatanavin R; Suyono S; Benard F; Casey R; Brock G; Belanger A
Int J Impot Res; 2001 Dec; 13(6):317-21. PubMed ID: 11918246
[TBL] [Abstract][Full Text] [Related]
18. Intraurethral application of alprostadil in patients with failed inflatable penile prosthesis.
Benevides MD; Carson CC
J Urol; 2000 Mar; 163(3):785-7. PubMed ID: 10687977
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of PGE1 cream in the treatment of erectile dysfunction].
Jiang H; Xu QQ; Hong K; Wang XF; Zhu JC
Zhonghua Nan Ke Xue; 2003 Apr; 9(2):97-9. PubMed ID: 12749125
[TBL] [Abstract][Full Text] [Related]
20. MUSE therapy: preliminary clinical observations.
Werthman P; Rajfer J
Urology; 1997 Nov; 50(5):809-11. PubMed ID: 9372900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
